Does the recent publication of EPCORE FL-1 (Epcoritamab + R2) change your preferred 2L SOC for R/R FL?

The approval of the combination of epcoritamab + R2 for relapsed/refractory FL based on the data from the EPCORE FL-1 study has provided an additional effective option for the treatment of patients with relapsed/refractory FL, and I have incorporated it into my practice for patients in the 2L settin...

Partially! Epcoritamab certainly has a role in patients with FL who have more aggressive behaving disease but there is a plethora of choices in that setting. It may not be suitable for patients treated in the community away from my center because of the unique toxicities. It does have a role in that...

Efficacy data for epcoritamab plus R2 look great (the best I’ve seen for a fixed-duration regimen). Indirect comparison to epcoritamab alone and to tafasitamab plus R2 suggests that epcoritamab plus R2 is probably more effective. Below is a recent presentation of the latter comparison, though it inc...

Yes, it clearly has the longest and deepest responses for a 2nd-line-fixed-duration therapy. It is also chemo-free.